Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
92.57
-1.27 (-1.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomarin Pharmaceuticals
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
CLASS ACTION UPDATE for EAR, NNOX and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
October 27, 2021
NEW YORK, NY / ACCESSWIRE / October 27, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies....
From
Levi & Korsinsky, LLP
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 27, 2021
From
The Schall Law Firm
Via
Business Wire
LAWSUITS FILED AGAINST EAR, BMRN and RECAF -Jakubowitz Law Pursues Shareholders Claims
October 26, 2021
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...
From
Jakubowitz Law
Via
AccessWire
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
Product Safety
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 26, 2021
From
The Schall Law Firm
Via
Business Wire
CLASS ACTION UPDATE for HYRE, WDH and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
October 26, 2021
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies....
From
Levi & Korsinsky, LLP
Via
AccessWire
Topics
Initial Public Offering
Lawsuit
Exposures
Financial
Legal
Product Safety
BMRN ALERT: BioMarin Pharmaceutical Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
October 26, 2021
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPLT, BMRN and AMRN
October 26, 2021
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to...
From
The Klein Law Firm
Via
AccessWire
Topics
Fraud
Intellectual Property
Exposures
Intellectual Property
Legal
Product Safety
SHAREHOLDER ALERT: HEPS BMRN AMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
October 26, 2021
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a...
From
The Law Offices of Vincent Wong
Via
AccessWire
Topics
Fraud
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Lawsuits Filed Against HYZN, NNOX and BMRN - Jakubowitz Law Pursues Shareholders Claims
October 25, 2021
NEW YORK, NY / ACCESSWIRE / October 25, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...
From
Jakubowitz Law
Via
AccessWire
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
Product Safety
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN
October 25, 2021
From
Rosen Law Firm
Via
Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
October 16, 2021
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other featured articles discuss which companies may benefit...
Via
Benzinga
NASDAQ:BMRN Investor Notice: Investigation over Possible Securities Laws Violations by BioMarin Pharmaceutical Inc.
September 22, 2021
San Diego, CA -- (SBWIRE) -- 09/22/2021 -- BioMarin Pharmaceutical Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Exposures
Product Safety
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug
September 09, 2021
Stifel
Via
Benzinga
Exposures
Product Safety
Price To Earnings Ratio Insights For Biomarin Pharmaceutical
September 07, 2021
In the current market session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is trading at $80.65, after a 5.06% drop. However, over the past month, the stock spiked by...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 07, 2021
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
September 09, 2021
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE:
Via
Benzinga
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder
September 07, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene...
Via
Benzinga
Exposures
Product Safety
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval
August 27, 2021
The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The...
Via
Benzinga
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
August 20, 2021
All it will take is an FDA approval and a partial repeat of history.
Via
The Motley Fool
Exposures
Product Safety
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
July 29, 2021
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues,...
Via
Talk Markets
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
July 29, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to...
Via
Benzinga
BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript
July 29, 2021
BMRN earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biomarin Pharmaceutical: Q2 Earnings Insights
July 28, 2021
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the...
Via
Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy
July 21, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from open-label Phase 1/2 trial of valoctocogene roxaparvovec, an investigational gene therapy...
Via
Benzinga
BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22
July 15, 2021
The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene...
Via
Benzinga
Exposures
Product Safety
EMA's Advisory Committee Backs Approval Of BioMarin's Dwarfism Candidate
June 25, 2021
European Medical Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of BioMarin...
Via
Benzinga
EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy
May 24, 2021
The European Medicines Agency (EMA) has granted its request for accelerated assessment review to BioMarin Pharmaceutical Inc’s (NASDAQ: BMRN)...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.